|
[Related PubMed/MEDLINE]
Total Number of Papers: 834
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
90 YEARS OF PROGESTERONE: Steroid receptors as MAPK signaling sensors in breast cancer: let the fates decide. |
AR, GR, PR, SRs |
| 2 |
2020 |
AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors. |
AR, BC |
| 3 |
2020 |
Bisphenol A-induced mechanistic impairment of decidualization. |
BPA, Egr-1, eNOS, NO, PR, SGK1 |
| 4 |
2020 |
Effect of level of hormone-receptor expression on treatment outcomes of "triple-positive" early-stage breast cancer. |
DFS, HER2, HR, PR |
| 5 |
2020 |
Effect of neoadjuvant therapy on breast cancer biomarker profile. |
HER2, IHC, NAT, PR |
| 6 |
2020 |
Epigenetic Regulation and Dietary Control of Triple Negative Breast Cancer. |
HER2, PR, TNBC |
| 7 |
2020 |
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. |
DCIS, PgR |
| 8 |
2020 |
Hyaluronic Acid Present in the Tumor Microenvironment Can Negate the Pro-apototic Effect of a Recombinant Fragment of Human Surfactant Protein D on Breast Cancer Cells. |
EGF, HA, PR, rfhSP-D, SP-D |
| 9 |
2020 |
Impact of Eukaryotic Translation Initiation Factors on Breast Cancer: Still Much to Investigate. |
BC, eIFs, PR |
| 10 |
2020 |
Invitro profiling of the potential endocrine disrupting activities affecting steroid and aryl hydrocarbon receptors of compounds and mixtures prevalent in human drinking water resources. |
AhR, AR, GR, PR, TCDD |
| 11 |
2020 |
KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature. |
CA125, CK5-6, CK7, EMA, PAX8, PR |
| 12 |
2020 |
Long-term consumption of non-fermented and fermented dairy products and risk of breast cancer by estrogen receptor status - Population-based prospective cohort study. |
CIs, HRs, PR |
| 13 |
2020 |
microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers is Mainly Dependent on HER2 Status-A Pilot Study. |
FC, miRNA, PgR |
| 14 |
2020 |
Molecular interactions of vinclozolin metabolites with human estrogen receptors 1GWR-alpha and 1QKM and androgen receptor 2AM9-beta: Implication for endocrine disruption. |
AR, VCZ |
| 15 |
2020 |
Molecular Investigation on a Triple Negative Breast Cancer Xenograft Model Exposed to Proton Beams. |
BC, GEP, HER2, IHC, PR, PT, RT, TNBC |
| 16 |
2020 |
PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old. |
IBC, IC, PD-L1, PDL1IC, PDL1TC, PR, TC, TILs |
| 17 |
2020 |
Pembrolizumab and atezolizumab in triple-negative breast cancer. |
HER2, ICI, PD-L1, PgR, TILs, TNBC |
| 18 |
2020 |
Pilot study of global endocrine disrupting activity in Iowa public drinking water utilities using cell-based assays. |
AhR, AR, EDCs, GR, TR |
| 19 |
2020 |
Recurrence/Regrowth in Grade I Meningioma: How to Predict? |
AR, PR, TMA |
| 20 |
2020 |
Role of Melatonin in Breast Carcinoma: Correlation of Expression Patterns of Melatonin-1 Receptor With Estrogen, Progesterone, and HER2 Receptors. |
MT1, PR |
| 21 |
2020 |
SNPs in the interleukin-12 signaling pathway are associated with breast cancer risk in Puerto Rican women. |
BC, IL-12, PR, SNPs |
| 22 |
2020 |
The impact of selected risk factors among breast cancer molecular subtypes: a case-only study. |
BC, BI-RADS, CI, ORs, PR |
| 23 |
2020 |
The mixture effects of bisphenol derivatives on estrogen receptor and androgen receptor. |
AhR, AR, BPA, BPF, BPS, BPs, EDC |
| 24 |
2020 |
The role of histopathologic testing on apocrine carcinoma of the breast. |
GCDFP-15, PR |
| 25 |
2019 |
Autism spectrum disorders, endocrine disrupting compounds, and heavy metals in amniotic fluid: a case-control study. |
AF, AhR, AR, ASD, EDCs, FDR, OR, PFAS, PFOS |
| 26 |
2019 |
Clinicopathological characteristics of metaplastic breast cancer-analysis of the basic immunohistochemical profile andcomparison with other invasive breast cancer types. |
MpBC, PR |
| 27 |
2019 |
Dietary Glycemic Index and Glycemic Load and Risk of Breast Cancer by Molecular Subtype in Mexican Women. |
BC, GI, GL, HER2, PR, TN |
| 28 |
2019 |
Evaluation of the value of GATA3 combined with E-cadherin in the diagnosis of breast cancer. |
ELISA, HER2, PR |
| 29 |
2019 |
Expression of androgen, estrogen, and progesterone hormone receptors in the penile tissues of children with different types of hypospadias. |
AR, PR |
| 30 |
2019 |
HER-2/Neu and Hormone Receptor Analysis in Breast Carcinomas and Their Association with Clinicopathologic Parameters. |
FISH, IC-NST, IHC, PR |
| 31 |
2019 |
Hormone- and HER2-receptor assessment in 33,046 breast cancer patients: a nationwide comparison of positivity rates between pathology laboratories in the Netherlands. |
IBC, PR |
| 32 |
2019 |
Hypofractionated radiation in older women with breast cancer. |
IMRT, PR |
| 33 |
2019 |
Imaging Cobalamin Uptake within Malignant Breast Tumors In Vivo. |
Cbl, DEX, HER2, p.i, PC, PR, SPECT, TN, WB-P |
| 34 |
2019 |
Liraglutide treatment effects on rat ovarian and uterine tissues. |
CAT, FSH, GLP-1, LH, MDA, PR, SOD |
| 35 |
2019 |
Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses' Health Studies. |
CI, HR, NHS, PR |
| 36 |
2019 |
Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. |
PD, PFS, PR, QOL |
| 37 |
2019 |
Prognostic markers in salivary gland cancer and their impact on survival. |
AR, DFS, EGFR, HER2, OS, PD-L1, PR, SGC, TIMC |
| 38 |
2019 |
Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material. |
NAT, PR |
| 39 |
2019 |
Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas. |
PR |
| 40 |
2019 |
Suboptimal concordance in testing and retesting results of triple-negative breast carcinoma cases among laboratories: one institution experience. |
PR, TNBC |
| 41 |
2019 |
Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018. |
IHC, LI, PR |
| 42 |
2019 |
Wnt pathway targeting reduces triple-negative breast cancer aggressiveness through miRNA regulation in vitro and in vivo. |
3'-UTRs, HER2, miRNAs, PR |
| 43 |
2019 |
[10]-Gingerol Affects Multiple Metastatic Processes and Induces Apoptosis in MDAMB- 231 Breast Tumor Cells. |
HER2, PR, TNBC |
| 44 |
2018 |
Assessment of endocrine disruption and oxidative potential of bisphenol-A, triclosan, nonylphenol, diethylhexyl phthalate, galaxolide, and carbamazepine, common contaminants of municipal biosolids. |
AhR, AR, BPA, DEHP, TCS, tNP, TTR |
| 45 |
2018 |
Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells. |
HER2, PR, TNBC |
| 46 |
2018 |
Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review. |
CI, MBC |
| 47 |
2018 |
Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer. |
PgR, uPA |
| 48 |
2018 |
ER-/PR+ subset of invasive breast carcinoma (IBC): a distinct phenotype with good prognosis. |
DFS, IBC, OS, PR |
| 49 |
2018 |
Estrogen and progesterone signalling in the normal breast and its implications for cancer development. |
PR |
| 50 |
2018 |
Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors. |
AR, PR, SDC, SGTs |
| 51 |
2018 |
Expression of hormone receptors in oropharyngeal squamous cell carcinoma. |
AR, HPV, OPSCC, PR |
| 52 |
2018 |
High level of C-type natriuretic peptide induced by hyperandrogen-mediated anovulation in polycystic ovary syndrome mice. |
AR, DHEA, hCG, LH, PCOS |
| 53 |
2018 |
Identification of mitochondrial hormone receptors in avian muscle cells. |
GR, PR, TR |
| 54 |
2018 |
Immunophenotypic profile of tumor buds in breast cancer. |
BC, HR, ngTMA, PgR |
| 55 |
2018 |
In Vitro Tissue Microarrays for Quick and Efficient Spheroid Characterization. |
PR |
| 56 |
2018 |
Incorporation of metabolic enzymes to improve predictivity of reporter gene assay results for estrogenic and anti-androgenic activity. |
AR |
| 57 |
2018 |
Interleukin 7 receptor alpha Thr244Ile genetic polymorphism is associated with susceptibility and prognostic markers in breast cancer subgroups. |
BC, HER2, IL-7, IL-7Ralpha, PR |
| 58 |
2018 |
Organized screening detects breast cancer at earlier stage regardless of molecular phenotype. |
PR |
| 59 |
2018 |
Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast Cancers |
PR, PRC, TNBCs |
| 60 |
2018 |
Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67. |
CI, DFS, HR, OR, PR, TMB |
| 61 |
2018 |
PROGNOSTIC IMPACT OF LOW ESTROGEN AND PROGESTERONE POSITIVITY IN LUMINAL B (HER2 NEGATIVE) BREAST CANCER. |
PR |
| 62 |
2018 |
Src Kinase Dependent Rapid Non-genomic Modulation of Hippocampal Spinogenesis Induced by Androgen and Estrogen. |
AR, DHT |
| 63 |
2018 |
SUMOylation Regulates Transcription by the Progesterone Receptor A Isoform in a Target Gene Selective Manner. |
PR |
| 64 |
2018 |
Ten-Year Survival after Liver Resection for Breast Metastases: A Single-Center Experience. |
PR |
| 65 |
2018 |
Tissue Expression of Prohibition-I and It's Relationship With Prognostic Factors in Breast Cancer. |
IHC, PHB, PR |
| 66 |
2017 |
Characterization of hormonal receptors and human epidermal growth factor receptor-2 in tissues of women with breast cancer at Muhimbili National Hospital, Dar es salaam, Tanzania. |
MNH, MRM, PgR, SPSS, TNBC |
| 67 |
2017 |
Clinicopathological features of patients with breast cancer aged 70 years or over. |
BC, DFS, HER2, LNI, LVI, OS, PgR, PNI |
| 68 |
2017 |
Collagen concentration on the facial skin of postmenopausal women after topical treatment with estradiol and genistein: a randomized double-blind controlled trial. |
GEN, UNIFESP |
| 69 |
2017 |
Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes. |
CBBCT, HER2, PR |
| 70 |
2017 |
Effect of Hydrochloric Acid Decalcification on Expression Pattern of Prognostic Markers in Invasive Breast Carcinomas. |
BC, HCl, IHC, PR |
| 71 |
2017 |
Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors. |
IDC, ILC, PR |
| 72 |
2017 |
Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer. |
CNB, DCIS, HER2, IBC, OR, PR |
| 73 |
2017 |
Evaluation of Immunohistochemistry-Equivocal (2+) HER2 Gene Status in Invasive Breast Cancer by Silver DNA in Situ Hybridization (SISH) and its Association with Clinicopathological Variables. |
PR, SISH |
| 74 |
2017 |
Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences. |
ASCO, BCI, PAM50, PR |
| 75 |
2017 |
Genome-wide miRNA, gene and methylation analysis of triple negative breast cancer to identify changes associated with lymph node metastases. |
PR, TNBC |
| 76 |
2017 |
Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : Amonocentric clinicopathologic analysis. |
AR, DFS, DMFS, EGFR, LRC, PD-L1-R, PR, SDC |
| 77 |
2017 |
Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with pure ductal carcinoma in situ (DCIS)? |
DCIS, IDC, MRI, PR |
| 78 |
2017 |
Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. |
CBR, EC, HR, HT, ORR, OS, PFS, PgR |
| 79 |
2017 |
Morphological and immunohistochemical characterization of spontaneous endometriosis in rhesus macaques (Macaca mulatta). |
CK, IHC, PR, SMA |
| 80 |
2017 |
Occurrence and In Vitro Bioactivity of Estrogen, Androgen, and Glucocorticoid Compounds in a Nationwide Screen of United States Stream Waters. |
AR, GR |
| 81 |
2017 |
Outcomes According to Breast Cancer Subtype in Patients Treated With Accelerated Partial Breast Irradiation. |
APBI, BCST, CSS, DFS, DM, IBTR, LA, LB, OS, PR |
| 82 |
2017 |
Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells In Vitro. |
PR, VDR |
| 83 |
2017 |
Prognostic role of progesterone receptor expression in a population-based analysis. |
HER2, PR |
| 84 |
2017 |
Prognostic value of primary tumor SUVmax on F-18 FDG PET/CT compared with semi-quantitative tumor uptake on Tc-99m sestamibi breast-specific gamma imaging in invasive ductal breast cancer. |
ANS, BSGI, IDC, PR, pTS, TNRs |
| 85 |
2017 |
Steroid and Xenobiotic Receptor Signalling in Apoptosis and Autophagy of the Nervous System. |
AhR, AR, GR, MR, PPARs, PR |
| 86 |
2017 |
Steroid hormone receptors and direct effects of steroid hormones on ram spermatozoa. |
PR |
| 87 |
2017 |
Synergistic Action of Genistein and Calcitriol in Immature Osteosarcoma MG-63 Cells by SGPL1 Up-Regulation. |
S1P, SGPL1, VDR |
| 88 |
2017 |
The Impact of Androgen Receptor Expression on Endometrial Carcinoma Recurrence and Survival. |
AR, ECs, PR |
| 89 |
2017 |
The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer. |
PR |
| 90 |
2017 |
The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. |
PR, TNBC |
| 91 |
2017 |
Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients. |
7NP, BLBCs, CK, DCIS, EGFR, HER2, IHC, PR, TNBCs |
| 92 |
2016 |
An overview of the effective combination therapies for the treatment of breast cancer. |
BC, PR, TNBC |
| 93 |
2016 |
Androgen receptor as potential therapeutic target in metastatic endometrial cancer. |
AR, PR |
| 94 |
2016 |
Bentamapimod (JNK Inhibitor AS602801) Induces Regression of Endometriotic Lesions in Animal Models. |
BWE, MMP-3, MPA, PR |
| 95 |
2016 |
beta-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases. |
--- |
| 96 |
2016 |
Case report of metastatic invasive breast lobular carcinoma to the urinary bladder. |
PR |
| 97 |
2016 |
CCR2-V64I genetic polymorphism: a possible involvement in HER2+ breast cancer. |
BC, HER2, PR |
| 98 |
2016 |
Circulating Tumor Cells in Breast Cancer: Correlation with Clinicopathological Parameters, Hormone Profile and MicroRNA Polymorphisms. |
PR |
| 99 |
2016 |
Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. |
BC, CTCs, PR |
| 100 |
2016 |
Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer. |
AR, CRPC, DES, PCa |
|
A Search Service for Abbreviation / Long Form
